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Abstract: 
The potential challenges to solve the poor solubility, limited chemical stability in vitro and in vivo after 
administration (i.e. short half-life), poor bioavailability and potentially strong side effects requiring drug 
enrichment at the site of action (targeting). This review describes the use of nanoparticulate carriers, developed in 
our research group, as one solution to overcome the dosage forms. The performance of ODTs depends on the 
technology used in their manufacture. The orally disintegrating property of these tablets is attributable to the quick 
ingress of water into the tablet matrix, which creates porous structure and results in rapid disintegration. Hence, the 
basic approaches to develop ODTs include maximizing the porous structure of the tablet matrix, incorporating the 
appropriate disintegrating agent and using highly water-soluble excipients in the formulation. Fast disintegrating 
tablets have better patient acceptance, compliance and possibly will tender enhanced biopharmaceutical properties, 
superior efficacy, and enhanced safety compared to conventional oral dosage forms. The perspective for such 
dosage forms is promising because of the accessibility of new technologies combined with strong market/patient 
acceptance. 
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INTRODUCTION: 
An orally disintegrating tablet (ODT) is defined as a 
solid dosage form that dissolves or disintegrates 
quickly in the oral cavity without the need for 
administration of water. The ODTs as uncoated 
tablets intended to be placed in the mouth where they 
disperse rapidly before being swallowed and as 
tablets which should disintegrate within 3min(1).  
Orally disintegrating tablets are claimed to be a better 
solution than conventional solid oral dosage forms 
(tablets and capsules) as the latter create problems for 
pediatric, geriatric, bedridden, nauseous or non-
complient patients (2). After meeting saliva ODTs 
disintegrate immediately and produce a suspension 
that can be easily swallowed by the patient (3). The 
active ingredients in solution are more rapidly 
absorbed through the pre-gastric route from the 
mouth, pharynx and esophagus and through 
gastrointestinal epithelium to produce the desired 
effect (4). ODTs are preferred for people suffering 
from dysphagia, institutional psychiatric patients as 
well as hospitalized patients suffering from a variety 
of disorders such as stroke, thyroid disorder, 
Parkinson’s disease and other neurological disorders 
like multiple sclerosis and cerebral palsy. Dysphagia 
is a condition marked by the difficulty in swallowing 
and it has been reported that about 35 % of the 
general population, in addition to 30–40 % of elderly 
institutionalized patients and 18–22 % of all persons 
in long- -term care facilities, suffer from dysphagia 
(5). ODTs have also been found to be the dosage 
form of choice for patients suffering from nausea, 
vomiting or motion sickness. 
The use of nanoparticles as a drug-delivery approach 
for various difficult-to-formulate reagents is not a 
new concept. In pharmaceutics, nanoparticles are 
typically defined as a discrete internal phase 
consisting of an active pharmaceutical ingredient 
having physical dimensions, less than 1 micron in an 
external phase. Also, nanoparticles can be designed 
to form de novo when exposed to the appropriate 
biological fluid. The inability to achieve high drug 
loading, the cost of ingredients and processing, and 
the restricted number of suitable excipients have 
either to limit the broader use of these formulation 
approaches. which focuses on poorly water-soluble 
drugs, has addressed many of these major concerns 
and has successfully expanded the scope and use of 
nanoparticulates or nanosuspensions to include the 
oral, inhalation, intravenous, subcutaneous (SubQ) 
and intramuscular (IM), and ocular routes of delivery 
(6). 
Nanoparticles represent a very promising carrier 
system for the targeting of anti-cancer agents to 
tumors as they exhibit a significant tendency to 
accumulate in many tumors after intravenous 
injection. The development of appropriate vehicles to 
deliver new macromolecules coming out of the 
biotech industry is a challenge for pharmaceutical 
scientists. In many cases peptides are quite efficiently 
bound to nanoparticles (7). 
 
TECHNOLOGIES USED FOR DEVELOPING 
ORALLY DISINTEGRATING TABLETS 
Lyophilization/freeze-drying: 
The principle of the lyophilization technique is 
drying carried out at low temperature under 
conditions involving removal of water by 
sublimation. In this technique, the material is initially 
frozen below –18 °C and then reducing the pressure 
of the system and giving the necessary heat allows 
the sublimation process. This technique is extremely 
useful for heat sensitive drugs and biological. Here, 
the drug is physically entrapped in a water-soluble 
matrix, which is then freeze-dried to give a product 
that is highly porous and has a large surface area. 
Due to the porous nature of the product, the liquid 
medium penetrates the interior surface of the tablet 
thereby enhancing its disintegration. The tablets 
prepared by lyophilization disintegrate rapidly in less 
than 5s due to quick penetration of saliva in pores 
when placed in the oral cavity. The lyophilization 
process gives a glassy amorphous structure to the 
bulking agent and sometimes to the drug. In the 
lyophilization process, the API is dissolved or 
dispersed in an aqueous solution of a water-soluble 
excipients, such as gelatin, mannitol, starch or 
hydrophilic gum and the resultant mixture is poured 
onto the blister film (8).  
In the lyophilization process, the API is dissolved or 
dispersed in an aqueous solution of water-soluble 
excipients, such as gelatin, mannitol, starch or 
hydrophilic gum and the resultant mixture is poured 
onto the blister film. The filled blisters are passed 
through a cryogenic freezing process, specially 
designed to control the ultimate size of ice crystals. 
These frozen units are then transferred to large-scale 
freeze dryers for the sublimation process, where the 
remaining moisture is removed from the tablets. 
Finally, the freeze-dried open blisters are sealed via a 
heat-seal process to ensure stability and to protect the 
product from varying environmental conditions. The 
main advantage of lyophilization is elimination of the 
adverse effect of heat on the pharmaceutical product 
as APIs are not exposed to the elevated temperature. 
The ideal drug candidate for formulating ODTs by 
lyophilization is a tasteless, water insoluble drug with 
particle size preferentially smaller than 50 mm. 
Particle size plays an important role as larger 
particles than the mentioned ones might produce 
sedimentation problems during manufacturing (9). 
Water insoluble drugs are generally preferred 
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because incomplete freezing or collapse may occur 
with water soluble drugs at low eutectic freezing 
temperature. (10) used a mixture of mannitol and 
natural gum such as acacia gum, guar gum, xanthan 
gum or tragacanth as carrier material for preparation 
of an open matrix network structure. The mannitol 
concentration in stable ODT was reported to be at 
least 50 % (m/m) and the natural gum concentration 
of the solid dosage form was about 0.07 to 3.2 % 
(m/m). This study revealed an improvement in the 
properties of ODTs when the open matrix structure 
comprised mainly mannitol. 
 
Molding: 
ODTs prepared by molding, also known as solid 
dispersion, disintegrate within 5 to 15 s. Compression 
molding and heat molding is the two approaches to 
preparing ODTs by the molding technique. 
Compression molding involves moistening of the 
powder blend with a hydro-alcoholic solvent, 
followed by compression into mold plates to form a 
wetted mass. The wetted mass is then air-dried to 
remove the solvent. The compression force involved 
in compression molding is lower than that used for 
conventional tablet and hence molded tablets are less 
compact than conventional compressed tablets and a 
possess highly porous structure, which in turn 
increases disintegration and dissolution rates. In the 
heat molding process for the preparation of ODTs, 
molten mass containing a dispersed drug and/or 
dissolved drug is used (11). The disintegration time 
and dissolution rate of ODTs prepared using molding 
depend upon the dissolution or dispersion type of the 
drug. Hence, it can be said that the ODTs preparation 
using the molding process is easy and convenient at 
an industrial scale although cannot achieve 
disintegration time compared to that of lyophilized 
forms. The molded tablets typically do not possess 
great mechanical strength and can break during 
handling or when blister packs are opened. However, 
the addition of binders (acacia, polyvinyl 
pyrrolidone, PEG) gives sufficient consistency to the 
formulation and prevents tablet breaking (12). 
Cotton candy process: 
Cotton candy process utilizes a unique spinning 
mechanism to produce floss of crystalline structure. 
The process involves formation of a matrix of 
saccharides or polysaccharides by simultaneous flash 
melting and spinning. This results into formation of 
the candy floss matrix, which is then milled and 
blended with active ingredients and excipients and 
subsequently compressed into ODTs. To improve the 
flow properties and compressibility, the candy floss 
matrix may sometimes partially recrystallize, which 
imparts good mechanical strength and can 
accumulate a large quantity of drug. However, this 
process is not suitable for thermolabile drugs (13). 
 
Compaction: 
In the compaction process, a mixture of particulate 
matter is fed to a compression device which promotes 
agglomeration due to pressure. Continuous sheets of 
solid material or solid forms such as briquettes or 
tablets are produced. Compaction processes range 
from confined compression devices such as tableting 
to continuous devices such as roll presses, briquetting 
machines and extrusion. The following different 
techniques are based on the compaction mechanism. 
 
Crystalline transition process: 
ODTs are prepared by crystalline transition through 
compressing two saccharides having high and low 
compressibility/mold ability indices and are then 
subjected to the conditioning process (14). Transition 
from the amorphous to crystalline state is 
intentionally done by the conditioning process after 
tablet compression to achieve sufficient hardness and 
fast disintegration time. Fluidized bed granulator is 
commonly used for the crystalline transition process.  
 
Phase transition: 
The manufacturing ODTs using phase transition of 
sugar alcohol (SA). This method was mainly 
dependent upon the melting point of SA. The process 
involves compressing the powder containing two SAs 
of high and low melting points and subsequently 
heating the compressed mass at the temperature 
between their melting points. However, in case of 
talc, oral disintegration time did not change with an 
increase in hardness. Among the three lubricants 
studied, i.e., magnesium stearate, sodium stearyl 
fumarate and talc, talc was recommended as the most 
desirable lubricant for preparation of ODTs by phase 
transition of SA (16) . 
 
Sublimation:  
Conventional tablets with high water-soluble 
ingredients fail to disintegrate rapidly because of 
their low porosity and this suggests that the presence 
of a highly porous particle structure in the tablet 
matrix is an important factor for fast disintegration of 
ODT. In the sublimation process, volatile substances 
like camphor, ammonium carbonate, ammonium 
bicarbonate, benzoic acid, hexamethonium tetramine, 
naphthalene, phthalic anhydride, urea and urethane 
were used along with other excipients. Solvents such 
as cyclohexane/benzene were sometimes also used 
for further enhancement in the porous matrix 
formation. Volatilization of these materials 
eliminates the complicated process associated with 
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the lyophilization process, that is, sublimation of 
frozen water. 
 
Conventional methods: 
Different conventional methods such as direct 
compression, wet granulation and dry granulation are 
used in the preparation of ODTs. The relationship 
between disintegration time in the mouth and 
stationary time of upper punch displacement (STP) 
was studied using a tableting process analyzer. As the 
value of bulk density increased, STP became longer 
and disintegration time in the mouth was shorter. A 
formulation with bulk density greater than 0.5 g mL–1 
with the chosen compression force of 5kN produced 
a tablet which gave a disintegration time of less than 
60 s. Also, the hardness of the tablet was found to be 
greater than 3 kg if at least one compressible 
excipients was used in the formulation. (17). 
Direct compression method:  
Few drugs can be directly compressed into tablets of 
acceptable quality with good flow properties and 
stability under pressure. This technique is now 
applied to the preparation of ODTs if good tablet 
disintegrants, superdisintegrants and sugar-based 
excipients are available. Disintegration of the tablets 
prepared by direct compression depends upon the 
single or combined effect of disintegrants, water 
soluble excipients and effervescent agents. 
Superdisintegrants are a family of disintegrants that 
are superior to the traditional disintegrants in 
promoting the tablets to disintegrate into their 
primary particles when placed in an aqueous 
environment and are efficient at concentrations as 
low as 2–5 %. 
The commonly used superdisintegrants in ODTs are summarized in Table. 
 
 
SUPERDISINTEGRANTS EMPLOYED IN ODTS 
Superdisintegrant Chemical structure Physical properties Mechanism Of action 
Crospovidone (Kollidon 
CL, Polyplasdone XL 
Synthetic homopolymer  of 
cross-linked N-vinyl-2-
pyrrolidone 
Water insoluble, spongy in 
nature so gives a porous 
tablet, smoother mouth feel 
Capillary action absorbs 
water leading to swelling 
Croscarmellose sodium 
(Ac-Di-Sol®, Nymce 
ZSX®, Primellose®, 
Solutab®, Vivasol®) 
Crosslinked form of sodium 
CMC 
Swells in two dimensions, 
swells 4–8 folds 
in < 10 s 
Swelling 
Sodium starch 
glycolate (Explotab®, 
Primogel®, Vivastar P) 
Sodium salt of 
carboxymethyl 
ether of starch 
Swells in three dimensions 
and at high concentration, 
serves as sustained-release 
matrix, Insoluble in organic 
solvents, disperse in cold 
water 
Water uptake followed by 
rapid and 
Enormous swelling 
Sodium alginate 
(Kelcosol, Keltone, 
Protanal) 
Sodium salts of alginic acid Hygroscopic in nature and 
slowly soluble in water 
 Swelling 
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Soypolysaccharides Natural 
polysaccharide 
Does not contain any starch 
or sugar 
Wicking 
ECG-505 (carmellose 
calcium) 
Calcium salt of CMC Disintegration time 80 s Swelling 
Ion exchange resin 
(Indion 414, Indion 
234, Tulsion 234, 
Tulsion 344, Amberlite 
IPR 88) 
  Swelling 
Gas evolving 
disintegrants 
(citric acid, 
tartaric acid, sodium 
bicarbonate) 
Effervescence 
substance 
Evolution of CO2 after 
contact with fluid 
In contact with 
water liberates CO2 that 
disrupts the tablet 
 
Wet granulation method: 
A new method for fast melting tablets formed by wet 
granulation based on highly plastic granules. If a 
plastic material is polymeric, then it is essential to 
prevent formation of a viscous layer of the material at 
tablet surface when it dissolves in aqueous medium. 
One way of making such tablets is to mix the plastic 
material with water penetration enhancers at certain 
ratios and compress them at low pressure. These 
results in plastic deformation of plastic materials, 
creating intimate contact among the particles required 
for forming bonds between the particles. In this 
process, the plastic particles are separated by water 
penetration enhancing particles, which prevent 
formation of a viscous layer on the tablet surface. 
Highly plastic granules were produced by the wet 
granulation method. 
Nanoparticles are solid colloidal particles ranging in 
size from 10 nm to 1000 nm. They consist of 
macromolecular materials in which the active 
principle is dissolved, entrapped or encapsulated, 
and/or to which the active principle is absorbed or 
attached. Nanoparticles have been studied 
extensively as particulate carriers in several 
pharmaceutical and medical fields. The group of 
Speiser initiated the research in the 1970s. They were 
initially devised as carriers for vaccines and 
anticancer drugs. Nanoparticulate technology is 
progressing through the development of new 
approaches in the field of drug delivery. 
 
APPLICATIONS OF NANOPARTICLES 
Nanoparticles, in general, can be used to provide 
targeted (cellular/tissue) delivery of drugs, to sustain 
drug effect in target tissue, to improve oral 
bioavailability to solubilize drugs for intra-vascular 
delivery and to improve the stability of therapeutic 
agents against enzymatic degradation. Nanoparticles 
formulated as amorphous spheres show higher 
solubility than standard crystalline formulations, thus 
improving the poor aqueous solubility of the drug 
and hence its bioavailability. Nanoparticles can be 
formulated as injections consisting of spherical 
amorphous particles which do not aggregate, hence 
they can be safely administered by the intravenous 
route. Since no co-solvent is used to solubilize the 
drug, the overall toxicity of the formulation is 
reduced. Nanoparticles represent a very promising 
carrier system for the targeting of anti-cancer agents 
to tumors as they exhibit a significant tendency to 
accumulate in a number of tumors after intravenous 
injection. The first anticancer drug bound to 
nanoparticles was actinomycin D. Over the last 20 
years, considerable progress has been made in the 
preparation of well-characterized nanoparticle 
formulations loaded with a variety of anticancer 
agents. Nano capsules may have the potential to 
deliver drugs to the lymph node through tissue spaces 
by local administration. The cosmetic applications of 
nanoparticles are currently under investigation. A 
cosmetic product containing nanocapsules of vitamin 
E, Primordiale1 has recently been launched (18). 
 
TECHNOLOGIES USED FOR DEVELOPING 
NANOPARTICULATE DRUG DELIVERY 
SYSTEMS 
Polymeric nanoparticles: 
Polymeric nanoparticles as drug delivery systems 
usually exhibit a long shelf life and a good stability 
on storage. Nanoparticles are superior to liposomes in 
targeting them to specific organs or tissues by 
adsorbing and coating their surface with different 
substances Polymeric nanoparticles are solid 
colloidal particles consisting of non-biodegradable 
synthetic polymers or biodegradable macromolecular 
materials of synthetic, semisynthetic or natural 
origin. According to the process used for the 
preparation of nanoparticles, nanospheres or 
nanocapsules can be obtained. Nanocapsules are 
vesicular systems in which the drug is confined to a 
cavity surrounded by a unique polymeric membrane. 
Nanospheres are matrix systems in which the drug is 
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dispersed throughout the particles. Although both 
types of active ingredients may be incorporated, most 
often they are hydrophilic in the case of nanospheres 
and lipophilic in the case of nanocapsules. Polymeric 
nanoparticles including nanospheres and 
nanocapsules can be prepared according to numerous 
methods.  
The major disadvantages of polymeric nanoparticles 
are their relatively slow biodegradability, which 
might cause systemic toxicity. Apart from polymer 
accumulation on repeated administration, toxic 
metabolites may be formed during the 
biotransformation of polymeric carriers, for example, 
formaldehyde as a metabolite of polycyanoacrylates. 
The formation of larger polymer particles and lumps 
cannot be avoided totally in large scale production of 
nanoparticles. The system also suffers from the lack 
of a cost-effective large scale production method 
yielding a product of a quality being acceptable by 
the regulatory authorities. Also polymeric 
nanoparticles possess limited drug loading capacity. 
 
Solid lipid nanoparticles (SLN): 
Solid lipid nanoparticles have been developed as 
alternative delivery system to conventional polymeric 
nanoparticles. The solid lipid nanoparticles (SLN) are 
sub-micron colloidal carriers (50–1000 nm) which 
are composed of a physiological lipid, dispersed in 
water or in an aqueous surfactant solution. Solid lipid 
nanoparticles combine advantages of polymeric 
nanoparticles, fat emulsions and liposomes, and 
avoid some of their disadvantages. They are 
biodegradable, biocompatible and non-toxic. The 
possibility of large scale production of SLN is an 
important feature.  
Advantages of SLN are: 
1. Avoidance of coalescence leads to enhanced 
physical stability. 
2. Reduced mobility of incorporated drug molecules 
leads to reduction of drug leakage. 
3. Static interface solid/liquid facilitates surface 
modification. 
The drug release can be controlled by varying the 
carrier matrices as well as by the choice of 
emulsifier. Besides parenteral administration, solid 
lipid nanoparticles are also suitable for other routes 
of administration and might be an interesting carrier 
system for the per oral administration of poorly 
water-soluble drugs with low per oral bioavailability. 
An advantage of the emulsified lipid particles might 
be their improved wet ability in gastrointestinal 
fluids. 
This problem has been overcome by the new 
generation of solid lipid nanoparticles, the so called 
nanostructured lipid carriers (NLC). These particles 
are characterized as forming on purpose an imperfect 
lipid particle matrix. This matrix gives much more 
room to incorporate drugs, the drug loading is 
increased. To achieve this, spatially very different 
lipid molecules are used for particle production. The 
“old” SLN are made from a solid lipid and 
subsequent melting and homogenization. The NLC 
are made by mixing a solid lipid with a liquid lipid 
(oil), these lipid molecules are spatially so different 
that they form imperfect matrices. Of course, the 
blend needs to be chosen in a way that after 
homogenization and cooling the blend solidifies and 
is solid at body temperature. 
Nanosuspensions (drug nanoparticles) for many 
decades’ drug carriers have represented the only 
group of colloidal drug administration systems. 
Nowadays a fundamentally different group of 
dispersions i.e. nanosuspensions (drug nanoparticles) 
are also under investigation. Pharmaceutical 
nanosuspensions are usually very finely dispersed 
solid drug particles in an aqueous vehicle for both 
oral and topical use or for parenteral and pulmonary 
administration. The next development was 
transformation of a micronized drug powder into 
drug nanoparticles. In a nanosuspension, the overall 
bioavailability is improved by an increase in surface 
area and saturation solubility via particle size 
reduction. The drug microparticles are ground to 
nanoparticles in between the moving milling pearls. 
Preparation of DissoCubes involves dispersion of 
drug powder in a surfactant solution by a high-speed 
stirrer. First, the particle size is reduced in a jet mill. 
The obtained macro-suspension is passed through a 
high-speed homogenizer leading to the formation of a 
nanosuspension. The cavitation forces experienced 
are sufficient to disintegrate drug microparticles to 
nanoparticles. The Table compares features of 
NanoCrystals and DissoCubes(19). 
 
NEW DEVELOPMENTS IN DRUG 
NANOCRYSTALS 
DissoCubes are prepared by homogenizing drug 
powder dispersed in pure water. This is based on the 
fact that it was believed that cavitation is the major 
force to disintegrate large particles to drug 
nanocrystals. To obtain cavitation one needs to have 
a liquid with a high vapour pressure, i.e. water. 
Cavitation should not be present or only present at a 
very limited extent when homogenizing in liquids 
with a low vapour pressure, e.g. liquid oils (MCT) or 
liquid PEG. Recently, a new patent application was 
filed describing the production of drug NanoCrystals 
in non-aqueous media. In addition, it is also claimed 
to produce drug NanoCrystals in mixtures of water 
with water-miscible liquids (e.g. production in 
isotonic dispersions of glycerol-water).  
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Drug NanoCrystals are produced in melted PEG, the 
obtained nanosuspension is then filled straight away 
as liquid at 70 _C in hard gealtin or HPMC capsules. 
Cooling forms a solid matrix in the capsule which 
contains the drug nanocrystals in a finely dispersed 
form. In addition, stock dispersions of water-sensitive 
drugs can be prepared. Such a stock suspension in 
e.g. glycerol can then be diluted prior to parenteral 
administration using sterile water to yield on isotonic 
suspension  
 
The major advantages of nanosuspension technology 
are its general applicability to most drugs and its 
simplicity. Interesting special features of 
nanosuspensions are  
 
a.  Increase in saturation solubility and 
consequently an increase in the dissolution rate of the   
drug. 
b. Increase in adhesive nature, thus resulting in 
enhanced bioavailability. 
c. Increasing the amorphous fraction in the 
particles, leading to a potential change in the 
crystalline structure and higher solubility. 
d. Absence of ostwald ripening, producing 
physical longterm stability as an aqueous suspension. 
e. Possibility of surface-modification of 
nanosuspensions for site specific delivery. 
f. Possibility of large-scale production, the 
pre-requisite for the introduction of a delivery system 
to the market. 
 
DRUG NANO PARTICLES TOWARDS 
SOLUBILITY CHALLENGE 
It is estimated that ~40% of active substances 
identified through combinatorial screening programs 
are difficult to formulate as a result of their lack of 
significant solubility in water. In one sense, this is 
understandable. If a molecule must penetrate a 
biological membrane to be absorbed, the molecule 
generally must possess some hydrophobic or 
lipophilic characteristics. The classical approach to 
deal with this issue is to generate various salts of a 
poorly water-soluble molecule so as to improve 
solubility while retaining biological activity. The 
problem is that, frequently, these approaches are not 
successful, and the molecule is abandoned early on in 
its development process or the product is launched 
with suboptimal properties including poor 
bioavailability, lack of fed/fasted equivalence, lack of 
optimal dosing, presence of extra excipients that pose 
limitations with respect to dose escalation, and 
ultimately, poor patient compliance. When these 
types of situations arise, a nanoparticles formulation 
approach has proven to be very useful and invaluable 
in all stages of the drug development and has opened 
opportunities for revitalizing marketed products with 
suboptimal delivery. 
 
NANOPARTICLE FORMULATIONS 
No matter what approach is taken to generate drug 
nanoparticles, in comparison to particulates greater 
than 1 micron, surface area is increased. This 
increase in surface area and surface interactions can 
be positively used to enhance the dissolution rate and 
provide a platform for controlling the 
pharmacokinetic properties of the dosage form. 
However, unless properly dampened, this tremendous 
increase in surface energy can cause the nanometer-
sized drug particles to spontaneously aggregate into a 
more thermodynamically stable state. It should be 
emphasized that surface stabilization does not 
necessarily involve chemical grafting of the surface 
stabilizer to the molecule. Stabilization is typically 
driven by the mere adsorption of the stabilizer to the 
surface of the poorly water-soluble compound. 
 
For instance, if a poorly water-soluble compound is 
an acid or a base, the pH of the fluid phase can be 
adjusted so as to minimize ionization; that is, acids 
would be processed under more acidic conditions, 
and free bases would be processed at a higher pH. 
Nanoparticle dispersions generated using 
NanoCrystal technology consist of drug and 
stabilizer, and most commonly, the fluid phase is 
water. These dispersions are processed using a high-
energy media mill with highly cross-linked 
polystyrene which provides a highly durable milling 
media resulting inefficient processing of crude drug 
crystals to homogenous nanoparticle–nanocrystalline 
dispersion with a particle size approximately 1 
micron or less. The key characteristics of 
NanoCrystal formulations for poorly water-soluble 
molecules are 
1) The versatility of the approach: suitable for 
many different classes of compounds, provided the 
aqueous solubility is less than 10 mg/ml. 
2) The potential to achieve formulations with 
high drug loading: 300 mg/g or (30% w/w). 
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3) A drug-to-stabilizer ratio on a weight basis 
typically 10:1 or lower: 30% drug to 3% or lower 
stabilizer concentration. 
4) Usefulness for all routes of administration: 
oral, pulmonary, intravenous,  IM and ophthalmic. 
5) The ability to be readily post processed into 
most commonly used dosage forms: tablets, capsules 
and sterile products. 
 
NANOPARTICLES:  
IMPROVED PERFORMANCE 
The activity of a compound depends on its ability to 
dissolve and interact with the relevant biological 
target, either through dissolution and absorption or 
dissolution and receptor interaction. The poor 
bioavailability of poorly water-soluble molecules that 
are not permeation-rate limited can be attributed to 
dissolution- rate kinetics. The dissolution rate is 
directly proportional to the surface area of the drug, 
according to the Noyes-Whitney model for 
dissolution kinetics. Drug crystals reduced in size 
from 10 microns to 100-nm particles generate a 100-
fold increase in surface-area-to-volume ratio. If the 
bioavailability of a poorly water-soluble compound is 
dissolution- rate limited, approaches that afford 
delivery using nanometer-sized particles of drug 
improve bioavailability by enhancing dissolution. 
This maximizes the amount of soluble drug that is 
free to be absorbed. This is especially true for poorly 
water-soluble compounds absorbed at a defined 
region of the gastrointestinal tract(20). 
 
 
 
CONCLUSION: 
Nanotechnology is the engineering and 
manufacturing of materials at the atomic and 
molecular scale. In its strictest definition from the 
National Nanotechnology Initiative, nanotechnology 
refers to structures roughly in the 1−100 nm size 
regime in at least one dimension. Despite this size 
restriction, nanotechnology commonly refers to 
structures that are up to several hundred nanometers 
in size and that are developed by top-down or 
bottom-up engineering of individual components. 
Herein, we focus on the application of 
nanotechnology to drug delivery and highlight 
several areas of opportunity where current and 
emerging nanotechnologies could enable entirely 
novel classes of therapeutics. Orodispersable tablets 
have better patient acceptance, compliance and 
possibly will tender enhanced biopharmaceutical 
properties, superior efficacy, and enhanced safety 
compared to conventional oral dosage forms. 
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